KRAS is the most commonly mutated oncogene in advanced, non-squamous, non-small cell
lung cancer (NSCLC) in Western countries. Of the various KRAS mutants, KRAS G12C is the …

Background Among patients with resected, epidermal growth factor receptor (EGFR)–
mutated, stage IB to IIIA non–small-cell lung cancer (NSCLC), adjuvant osimertinib therapy …

Background Among patients with resectable early-stage non–small-cell lung cancer
(NSCLC), a perioperative approach that includes both neoadjuvant and adjuvant immune …

Details on diagnostic procedures are covered in the Supplementary Material Section 2,
available at https://doi. org/10.1016/j. annonc. 2022.12. 009. See Supplementary Figure S1 …

Background Since their first introduction in clinical practice, immune checkpoint inhibitors
showed limited benefit in patients with NSCLC harboring EGFR mutations. With the rationale …

Importance Clinical interpretation of complex biomarkers for precision oncology currently
requires manual investigations of previous studies and databases. Conversational large …

Summary Background Tumor Treating Fields (TTFields) are electric fields that disrupt
processes critical for cancer cell survival, leading to immunogenic cell death and enhanced …

Abstract Introduction In CheckMate 227 Part 1, nivolumab plus ipilimumab prolonged overall
survival (OS) versus chemotherapy in patients with metastatic NSCLC, regardless of tumor …

Purpose: Combination of chemotherapy with programmed cell death 1 (PD-1) blockade is a
front-line treatment for lung cancer. However, it remains unknown whether and how …

Background The expression level of the programmed cell death ligand 1 (PD-L1) appears to
be a predictor for response to immunotherapy using checkpoint inhibitors in patients with …